A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Rationale: IL-13 is a potential therapeutic target for idiopathic pulmonary fibrosis (IPF); preclinical data suggest a role in tissue fibrosis, and expression is increased in subjects with rapidly progressing disease. Objectives: Investigate efficacy and safety of tralokinumab, a human anti–IL-13 monoclonal antibody, in subjects with mild to moderate IPF. Methods: Subjects received tralokinumab (400 or 800 mg), or placebo, intravenously every 4 weeks for 68 weeks. The primary endpoint was change from baseline to Week 52 in percent predicted FVC in the intention-to-treat population. Exploratory analyses included assessment of clinical response in subgroups with baseline serum periostin concentration above/below median. Measurements and Main Results: The study was stopped due to lack of efficacy after interim analysis. Neither tralokinumab 400 mg nor tralokinumab 800 mg met the primary endpoint; least-squares mean difference (95% confidence interval) percent predicted FVC from baseline to Week 52: −1.77 (−4.13 to 0.59) (P = 0.140) and −1.41 (−3.73 to 0.91) (P = 0.234), respectively. The primary endpoint was also not met in either treatment group in subgroups defined by periostin baseline concentration. The percentage of subjects with decline in percent predicted FVC greater than or equal to 10% at Week 52 was numerically greater for tralokinumab-treated subjects compared with placebo. The most common treatment-emergent adverse events for tralokinumab 400 mg, tralokinumab 800 mg, and placebo were cough (17.5, 30.5, 22.8%), IPF progression and exacerbation (21.1, 16.9, 22.8%), and upper respiratory tract infection (17.5, 20.3, 12.3%), respectively. Conclusions: Tralokinumab demonstrated an acceptable safety and tolerability profile but did not achieve key efficacy endpoints. Clinical trial registered with www.clinicaltrials.gov (NCT01629667).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, systemic administration of recombinant IFNγ (which would simulate the presence of Th1 biology) and monoclonal antibody-mediated neutralization of IL-13 (which would specifically target Th2 responses) failed to demonstrate efficacy in randomized, placebo-controlled trials of patients with IPF (141, 142).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [142]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 23 · Cited by 129
Research works printed but not linked: 2
- Glassberg, 2017, Effect of pirfenidone on breathlessness as measured by the UCSD-SOBQ score in patients with idiopathic pulmonary fibrosis (IPF) with moderate lung function impairment [abstract], Am J Respir Crit Care Med, 195, A5406
- Duguid, 2015, IL-13 is a driver of pulmonary fibrosis in the Fra-2 transgenic mouse model [abstract], Am J Respir Crit Care Med, 191, A3441
Metadata
- Authors
- Parker, J. M., Glaspole, I. N., Lancaster, L. H., Haddad, T. J., She, D., Roseti, S. L., Fiening, J. P., Grant, E. P., Kell, C. M., & Flaherty, K. R.
- Affiliations
- Clinical Development
- The Alfred Hospital (AU)
- Vanderbilt University (US)
- Tampa General Hospital (US)
- Clinical Biostatistics and Data Management
- Clinical Operations, and
- Translational Medicine, MedImmune, Gaithersburg, Maryland
- Product Development, MedImmune, Cambridge, United Kingdom; and
- University of Michigan (US)
- Corresponding author
- Roseti, Stephanie L.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-01
- Volume
- 197
- Issue
- 1
- Pages
- 94-103
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2744147503
- Cited by
- 129
- References
- 23
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 13 · 2023: 11 · 2022: 13 · 2021: 23 · 2020: 14 · 2019: 14 · 2018: 16
- FWCI
- 11.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- tralokinumab, idiopathic pulmonary fibrosis, IL-13, anti-IL-13 monoclonal antibody, forced vital capacity decline, periostin, treatment efficacy, drug safety and tolerability
- MeSH terms
- Aged, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Humans, Middle Aged, Prognosis, Severity of Illness Index, Biomarkers, Cell Adhesion Molecules, Survival Rate, Treatment Outcome, Risk Assessment, Maximum Tolerated Dose, Idiopathic Pulmonary Fibrosis, Patient Safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. https://app.cochat.ai/papers/10.1164/rccm.201704-0784oc
- The paper
- Parker, J. M., Glaspole, I. N., Lancaster, L. H., Haddad, T. J., She, D., Roseti, S. L., Fiening, J. P., Grant, E. P., Kell, C. M., & Flaherty, K. R. (2018). A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201704-0784oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.